TY - JOUR
T1 - Consensus guidelines and recommendations for infection prevention in multiple myeloma
T2 - a report from the International Myeloma Working Group
AU - Raje, Noopur S.
AU - Anaissie, Elias
AU - Kumar, Shaji K.
AU - Lonial, Sagar
AU - Martin, Thomas
AU - Gertz, Morie A.
AU - Krishnan, Amrita
AU - Hari, Parameswaran
AU - Ludwig, Heinz
AU - O'Donnell, Elizabeth
AU - Yee, Andrew
AU - Kaufman, Jonathan L.
AU - Cohen, Adam D.
AU - Garderet, Laurent
AU - Wechalekar, Ashutosh F.
AU - Terpos, Evangelos
AU - Khatry, Navin
AU - Niesvizky, Ruben
AU - Yi, Qing
AU - Joshua, Douglas E.
AU - Saikia, Tapan
AU - Leung, Nelson
AU - Engelhardt, Monika
AU - Mothy, Mohamad
AU - Branagan, Andrew
AU - Chari, Ajai
AU - Reiman, Anthony J.
AU - Lipe, Brea
AU - Richter, Joshua
AU - Rajkumar, S. Vincent
AU - Miguel, Jesús San
AU - Anderson, Kenneth C.
AU - Stadtmauer, Edward A.
AU - Prabhala, Rao H.
AU - McCarthy, Phillip L.
AU - Munshi, Nikhil C.
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/2
Y1 - 2022/2
N2 - Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.
AB - Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease, preventing infections is paramount. Optimal preventive strategies include vaccination against common pathogens, antimicrobial prophylaxis, infection control measures, and immunoglobulin replacement in a small subset of patients; however, there are no universally accepted guidelines for infection prevention. This Review provides a consensus statement from a panel of 36 experts with global representation, which was convened by The International Myeloma Society to review existing literature and current guidelines, address issues associated with the risk of infection and prevention of infectious complications in multiple myeloma in the context of emerging therapies, and offer recommendations for preventing these complications.
KW - Consensus
KW - Humans
KW - Infections/complications
KW - Multiple Myeloma/complications
UR - http://www.scopus.com/inward/record.url?scp=85123758879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123758879&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(21)00283-0
DO - 10.1016/S2352-3026(21)00283-0
M3 - Review article
C2 - 35114152
AN - SCOPUS:85123758879
SN - 2352-3026
VL - 9
SP - e143-e161
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 2
ER -